Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Peripheral Neuropathic Pain Clear all
Terminated Phase 4 Interventional Results available

Spinal Cord Stimulation for Painful Diabetic Neuropathy

NCT00487981
View directory record Official record
Conditions
Diabetic Neuropathy, Pain, Peripheral Neuropathy
Interventions
Precision Spinal Cord Stimulation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

NCT01521598
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
SKL11197, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Northport, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Phase 2 Interventional

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY4065967, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Not listed Phase 4 Interventional

Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy

NCT00123136
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
foot energizer
Device
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Briarcliff, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-128, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

NCT02355158
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes
Interventions
clonidine hydrochloride topical gel, 0.1%
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT03219320
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
NYX-2925, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 30, 2026, 2:45 AM EDT
Terminated Phase 4 Interventional Results available

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

NCT04707157
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
35
States / cities
Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT00375960
View directory record Official record
Conditions
Pain, Diabetic Neuropathies
Interventions
V3381, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Walnut Creek, California • Clearwater, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2007 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

NCT05177094
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY3526318, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
35
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

NCT04146896
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
NYX-2925 50 mg, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
35
States / cities
Fresno, California • Irvine, California • Lomita, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Sep 30, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tanezumab, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

NCT02927951
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Nerve Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
40 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Sep 30, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

NCT01537705
View directory record Official record
Conditions
Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions
Neuron012703 (Medical Food)
Drug
Lead sponsor
Targeted Medical Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 30, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT02643251
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions
Clonidine Hydrochloride Topical Gel, 0.1%, Clonidine Hydrochloride Gel Comparator
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
25
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 30, 2026, 2:45 AM EDT
Active, not recruiting Not applicable Interventional

Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy

NCT05777317
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
10 kHz SCS, CMM alone
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 30, 2026, 2:45 AM EDT
Terminated Phase 3 Interventional Results available

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

NCT01288937
View directory record Official record
Conditions
Idiopathic Peripheral Neuropathy
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 30, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies

NCT02842554
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN)
Interventions
EPT, Drug Placebo Administration, C
Other · Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 30, 2026, 2:45 AM EDT